JB/CALL/GILEAD SCIENCES/85/0.05/20.12.24

JB/CALL/GILEAD SCIENCES/85/0.05/20.12.24 Share Price

Warrant

GIZRJB

CH1263884632

Market Closed - Bid/Ask 08:50:00 28/05/2024 pm IST			After market 08:45:00 pm
0.02 ^CHF	-33.33%		0.015	-25.00%

3 months	-83.33%
6 months	-88.89%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart JB/CALL/GILEAD SCIENCES/85/0.05/20.12.24

Latest news about GILEAD SCIENCES, INC.

Namibian First Ladies Call for New HIV Medicine	05:36pm	AQ
Transcript : Gilead Sciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:20 PM	12/06
Arcus Completes Enrollment in Phase 3 Trial of Domvanalimab-Containing Regimen for Stomach Cancer	10/06	MT
Combination therapy may hold potential for severe viral hepatitis	06/06	AQ

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	GILEAD SCIENCES, INC.
Issuer	Bank Julius Bär
	GIZRJB
ISIN	CH1263884632
Date issued	05/06/2023
Strike	85 $
Maturity	20/12/2024 (190 Days)
Parity	20 : 1
Emission price	0.37 CHF
Emission volume	N/A
Settlement	cash
Currency	CHF

Technical Indicators

Highest since issue	0.43 CHF
Lowest since issue	0.02 CHF
Spread	0.01 CHF
Spread %	50.00%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company